Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Conditions: Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer Interventions: Drug: Tarlatamab; Drug: Durvalumab Sponsors: Amgen Not yet recruiting

https://clinicaltrials.gov/study/NCT06211036

Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials